Tirzepatide cost without insurance in 2026

Tirzepatide is sold as two brand-name medications made by Eli Lilly: Zepbound®, approved for weight management, and Mounjaro®, approved for type 2 diabetes. It is also prepared by compounding pharmacies and prescribed through telehealth programs. Paying cash, the price depends on which of those you buy, the dose, and whether you refill on time. Here is what each costs today and what's included.

Zepbound® self-pay prices, by dose (checked September 25, 2026)

Lilly sells Zepbound® self-pay through LillyDirect, as single-dose vials or as the KwikPen® (four weekly doses per pen). The vial and pen prices are the same. TrumpRx.gov lists Zepbound® at $299 and sends orders to LillyDirect.

The 45-day rule. The lower price at 7.5 mg and above applies only if you complete each refill purchase within 45 days of your last delivery. Miss that window and the regular price applies. Lilly says these savings end December 31, 2026.

List price. Before self-pay programs, Zepbound®'s list price was about $1,086 a month, according to the White House's November 2025 fact sheet. That is what insurers are billed before rebates, not what a self-pay patient pays at LillyDirect.

Medicare. Medicare's GLP-1 Bridge, from July 1, 2026 through December 31, 2027, covers Zepbound® in the KwikPen® form (not vials) for a $50 copay per one-month supply, for people with a Part D plan who meet the eligibility criteria, with prior authorization.

Compounded tirzepatide

Compounded tirzepatide is prepared by a licensed compounding pharmacy for an individual patient, on a licensed provider's prescription. Compounded medications are not FDA-approved. The FDA declared the tirzepatide shortage resolved on December 19, 2024, and ended its temporary enforcement flexibility for state-licensed pharmacies on February 18, 2025, so compounded tirzepatide must now meet the federal conditions for compounding without a shortage exception.

Telehealth programs set their own prices for compounded tirzepatide, and what's included varies. Some charge more as the dose goes up. Always ask what the price covers and what it will be at the dose you'd actually be on.

At Everlon, tirzepatide is $315/mo, if prescribed. That includes the provider evaluation, check-ins, dose adjustments and standard shipping, and the monthly price doesn't change with your dose. You'll only be charged if treatment is prescribed.

What to add up before you compare

1. The medication. From the table above for Zepbound®, or the program's price.
2. The prescriber. LillyDirect and TrumpRx sell the medication; they don't evaluate you or adjust your dose. You need your own prescriber, and their visits may cost extra.
3. Follow-up. Who answers your questions later, and what does that cost?
4. Shipping. Included, or extra?
5. The dose you'd be on. Brand prices change with the dose; check the price at yours, not only the starting one.
6. Timing rules. Zepbound®'s refill window, and when any introductory price ends.

FAQ

Is Zepbound® cheaper than compounded tirzepatide? It depends on the dose, the refill timing and what the compounded program includes. At 2.5 mg, Zepbound® is $299 a month for the medication alone. Add the cost of a prescriber and follow-up to compare it with an all-in program.

Does Medicare cover Zepbound®? Through the Medicare GLP-1 Bridge, for eligible people with Part D: the KwikPen® form, for a $50 copay per one-month supply, with prior authorization. Medicare.gov lists who qualifies.

Is compounded tirzepatide the brand product? No. It is a different preparation made by a compounding pharmacy, and compounded medications are not FDA-approved. It is not interchangeable with Zepbound® or Mounjaro®.

Is a prescription guaranteed? Never. A licensed provider reviews your health history and prescribes only when clinically appropriate.

Sources

• Zepbound® coverage, affordability and savings — Eli Lilly, accessed 2026-09-25
• Zepbound® — TrumpRx.gov, accessed 2026-09-25
• Fact sheet: most-favored-nation pricing agreements (November 6, 2025) — The White House, accessed 2026-09-25
• Medicare GLP-1 Bridge — CMS, accessed 2026-09-25
• Weight loss drugs — Medicare.gov, accessed 2026-09-25
• FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize — FDA, accessed 2026-09-25

Zepbound®, Mounjaro® and KwikPen® are registered trademarks of Eli Lilly and Company. LillyDirect and TrumpRx are programs of their respective owners. Everlon is not affiliated with or endorsed by Eli Lilly or TrumpRx.gov.